U.S., July 30 -- ClinicalTrials.gov registry received information related to the study (NCT07734844) titled 'A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants With DME - ALTO' on May 30.
Brief Summary: A Study to Evaluate the Efficacy and Safety of Tabirafusp Tedromer Compared to Aflibercept in Participants with Diabetic Macular Edema - ALTO
Study Start Date: Aug., 2026
Study Type: INTERVENTIONAL
Condition:
Diabetic Macular Edema (DME)
Intervention:
DRUG: Tabirafusp tedromer
Intravitreal injection
DRUG: Aflibercept (2.0 mg)
Intravitreal injection
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Kodiak Sciences Inc
Published by HT Digital Content Services with permission fr...